# A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

> **NCT03980002** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** FCR and Ibrutinib
- **DRUG:** BR and Ibrutinib
- **DRUG:** Ibrutinib and Thalidomide

## Key facts

- **NCT ID:** NCT03980002
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-15
- **Primary completion:** 2022-12-15
- **Final completion:** 2027-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980002, "A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03980002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*